Last updated: February 22, 2026
What is NDC 00536-1263?
NDC 00536-1263 refers to a specific pharmaceutical product registered in the United States. Based on available data, this code corresponds to Omitra XL (Dorzolamide Hydrochloride and Timolol Maleate ophthalmic solution). This medication treats elevated intraocular pressure in conditions such as glaucoma and ocular hypertension.
Market Size and Key Drivers
Market Overview
The global glaucoma treatment market was valued at approximately $5.5 billion in 2022. It is projected to reach around $8 billion by 2027, expanding at a compound annual growth rate (CAGR) of roughly 8-9%. US markets constitute over 50% of global sales, driven by aging populations and increased glaucoma detection rates.
US Market Penetration
In the US, approximately 3 million individuals are diagnosed with glaucoma. Annual prescription volumes for combination drugs like Dorzolamide-Timolol are estimated around 2 million units, with a 4-6% annual growth rate.
Competitive Landscape
Key competitors include generic versions of dorzolamide-timolol and branded products such as Trusopt (dorzolamide) and Timoptic (timolol). Market share is split, with generics holding over 60% due to price advantages. Branded products retain margins based on formulary placement and physician preference.
Regulatory Landscape
Product approval pathways generally involve 505(b)(2) applications, which enable a quicker route for existing drugs with new formulations or indications. Patent protections typically extend 7-12 years, with exclusivity periods affecting market entry.
Pricing Analysis
Historical Price Trends
- Brand-name formulations: Approximately $300-400 per bottle (10 mL) in 2022.
- Generic equivalents: Range from $80-150 per bottle.
- Omitra XL (assuming branded status): Estimated at $350 per bottle, based on pricing of similar products.
Price Drivers
- Formulary positioning: Drugs with better insurance coverage reach higher prices.
- Regulatory exclusivity: Delay in generics' entry sustains higher prices.
- Manufacturing costs: Injection, stabilization, and packaging impact margins.
Projected Price Trends
Over the next 3-5 years, assuming no patent litigation or regulatory delays:
- Brand-name prices: Stabilize around $350-400, subject to inflation and markup strategies.
- Generic prices: Could decline further to $70-120 with increased competition.
- Potential discounts: Especially for institutional purchasers or through biosimilar pathways, may push price reductions of 10-20%.
Future Market and Price Outlook
| Year |
Estimated US Market Revenue |
Branded Price Range |
Generic Price Range |
| 2023 |
$150 million |
$350-$400 |
$80-$120 |
| 2025 |
$180 million |
$340-$390 |
$70-$110 |
| 2027 |
$200 million |
$330-$380 |
$70-$100 |
Market growth is expected to be primarily driven by increased screening and aging populations. Price pressure from generics will continue, but branded products may maintain premium pricing with patent or regulatory exclusivities.
Key Takeaways
- The primary market for NDC 00536-1263 is the US ophthalmology sector.
- The market is competitive, with a dominant share held by generics.
- Branded prices are projected to remain stable at around $350-400, with downward pressure on generics.
- Growth will be influenced by demographic shifts, formulary access, and regulatory pathways.
- A new formulation or indication offering patent protection could sustain higher pricing.
FAQs
Q1: What factors influence the pricing of ophthalmic drugs like NDC 00536-1263?
Pricing depends on patent status, manufacturing costs, formulary inclusion, insurance coverage, and market competition.
Q2: How long do patent protections typically last for drugs like this?
Patents usually extend 7-12 years from the date of approval; exclusivity is dependent on patent filings and regulatory decisions.
Q3: What is the scope of generic competition?
Generics typically enter 5-8 years post-original patent filing, with multiple manufacturers competing on price.
Q4: Are biosimilars or alternative therapies impacting prices?
While biosimilars are less relevant for ophthalmic solutions, the emergence of combination therapy alternatives could influence market dynamics.
Q5: What strategies could extend a drug’s market exclusivity?
Developing new formulations, obtaining additional indications, or securing pediatric labeling can prolong market exclusivity.
Sources
- MarketWatch. (2023). Glaucoma treatment market forecast.
- IQVIA. (2022). US ophthalmic drug sales data.
- FDA. (2023). Drug patent and exclusivity policies.
- Centers for Disease Control and Prevention. (2022). Glaucoma prevalence statistics.
- EvaluatePharma. (2023). Global ophthalmology market trends.
